Memantine in the Treatment of Kleptomania

The University of Chicago

Status and phase: Completed; Phase 2

Conditions: Kleptomania

Treatments: Drug: Memantine

Study type: Interventional

Funder types: Other

Identifiers

NCT00880685

0901M56882

Details and patient eligibility

About

The goal of the proposed study is to evaluate the efficacy and safety of memantine in kleptomania.

Full description

The proposed study will consist of 8 weeks of treatment with memantine in 10 subjects with kleptomania. The hypothesis to be tested is that memantine will be effective in reducing the urges to steal in patients with kleptomania. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Enrollment: 12 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. men and women age 18-65
2. current KM using the clinician-administered Structured Clinical Interview for Kleptomania (SCI-K)
3. stealing behavior within 2 weeks prior to enrollment.

Exclusion criteria

1. infrequent stealing (i.e. less than one time per week) that does not meet proposed criteria for kleptomania (KM)
2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen
3. history of seizures
4. myocardial infarction within 6 months
5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential
6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions
7. clinically significant suicidality
8. current Axis I disorder determined by the Structured Clinical Interview for the DSM (SCID) and SCID-compatible modules for impulse control disorders (Grant et al., 2005), except for nicotine dependence
9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID
10. current or recent (past 3 months) DSM-IV substance abuse or dependence
11. positive urine drug screen at screening
12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline
13. previous treatment with memantine; and 14) treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Memantine

Experimental group

Description:

Memantine 10-30mg

Treatment:

Drug: Memantine